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The safety and efficacy of long-term oral milrinone ther•
apy were evaluated over a 2V2 year period in 100 patients 
who had severe congestive heart failure despite conven•
tional therapy. Long-term oral milrinone therapy (27 ± 
8 mg/day initial dose) was well tolerated; drug-related 
side effects occurred in only 11 % of patients and led to 
drug withdrawal in only 4% of patients. Of 94 patients 
evaluated after 1 month of therapy, 51 % had improved 
by at least one New York Heart Association functional 
class. Despite hemodynamic and clinical improvements, 
life table analysis showed a 39% mortality rate at 6 
months and a 63% mortality rate at 1 year of therapy. 
Characteristics at study entry that predicted death within 
6 months included more advanced functional class, im•
paired renal function, lower right ventricular ejection 
fraction, presence of nonsustained ventricular tachycar•
dia on 24 hour ambulatory electrocardiography, more 
Congestive heart failure, a common manifestation of the 
late stages of coronary, valvular or myocardial disease, af•
fects approximately 2 million individuals in the United States 
(1,2). Numerous studies of patients with heart failure have 
demonstrated an accelerated mortality which corresponds to 
a number of clinical indexes of severity, including New 
York Heart Association functional class, hemodynamic sta•
tus at rest and the presence of ventricular arrhythmia (3-12). 
Although a variety of therapeutic agents (cardiac glycosides, 
diuretics and vasodilators) are capable of producing short-
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impaired baseline hemodynamic function and absence 
of clinical improvement after 1 month of milrinone ther•
apy. 
Multivariate analysis selected lower baseline cardiac 
index and aortic systolic pressure as the most significant 
variables in predicting death; patients who died of pro•
gressive heart failure had less frequent use of antiar•
rhythmic drugs and greater increases in furosemide and 
milrinone doses during long-term follow-up than did those 
who died suddenly. Thus, although milrinone is well 
tolerated and produces early symptomatic benefits in 
approximately half of patients with congestive heart fail•
ure refractory to conventional therapy, there is no evi•
dence that it improves the high baseline mortality in this 
disorder. 
(J Am Coli CardioI1986;7:661-70) 
term hemodynamic and clinical improvement, and main•
taining this improvement to varying degrees and for various 
durations during long-term administration, there is no firm 
evidence that any of these groups of agents, adminisfered 
individually or in combination, prolong the survival of pa•
tients with severe congestive heart failure (13-15). 
Because many patients treated with conventional agents 
fail to achieve or maintain adequate clinical improvement, 
there has been ongoing interest in the development of orally 
active positive inotropic/vasodilator drugs such as the bi•
pyridine compound milrinone. We and other investigators 
(16-20) have previously described the acute hemodynamic 
and chronic clinical improvements produced by milrinone, 
but have not adequately assessed the influence of milrinone 
on patient survival. Such a study is particularly important, 
a~ some investigators (21-23) have suggested that inotropic 
therapy might actually have a deleterious long-term effect 
in patients with heart failure by predisposing them to myo•
cardial ischemia, ventricular arrhythmia or accelerated my-
0735-1097/86/$3 50 
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ocyte degeneration. In an effort to begin to address this 
important issue, the present report reviews our experience 
with long-term oral therapy in the first 100 patients with 
congestive heart failure to receive milrinone at the Beth 
Israel and Brigham and Women's Hospitals between July 
1982 and January 1985. 
Methods 
Study patients. This study is based on 100 patients with 
severe congestive heart failure despite treatment with dig•
italis glycosides, diuretics and one or more oral vasodilators. 
Eighty-five patients had received vasodilator therapy at max•
imally tolerated doses for at least 1 month immediately 
before entry into the study. The agents administered in•
cluded captopril in 51 patients (105 ± 75 mg/day), prazosin 
in 13 patients (5 ± 3 mg/day), hydralazine in 16 patients 
(139 ± 75 mg/day), long-acting nitrates as a single agent 
in 9 patients or combined with other vasodilators in 41 
patients, and nifedipine in 1 patient. In the remaining 15 
patients, vasodilator therapy had been attempted with one 
or more of these agents, but had been unsuccessful because 
of side effects or limiting hypotension. 
Each patient was evaluated by clinical examination, 24 
hour ambulatory electrocardiography, gated equilibrium 
radionuclide left and right ventriculography and serum 
chemistry determinations before enrollment. In addition, 
radioenzymatic measurement of plasma norepinephrine lev•
els at rest (20) was performed at baseline in 29 of the 35 
patients studied at the Brigham and Women's Hospital. The 
results of coronary angiography were available in 94 pa•
tients, and endomyocardial biopsy was performed in 22 of 
the 42 patients without underlying coronary artery disease. 
No patient with recent (within 3 months) myocardial in•
farction, significant ongoing angina pectoris, symptomatic 
ventricular arrhythmia despite drug therapy, surgically treat•
able valvular disease, biopsy-proved active myocarditis or 
clinically significant renal or pulmonary disease was included. 
Hemodynamic measurements. At entry, each patient 
underwent right heart catheterization after overnight with•
drawal from vasodilator and diuretic agents to evaluate base•
line hemodynamics and the response to acute intravenous 
milrinone administration. After paired baseline measure•
ments, the initial dose of milrinone was administered intra•
venously and hemodynamic measurements were repeated. 
Cardiac output was measured by the thermodilution or Fick 
technique, and other hemodynamic variables were calcu•
lated according to standard formulas (4). 
Oral milrinone therapy. After the intravenous milri•
none infusion, oral milrinone was administered three to six 
times per day in a total daily dose of 20 to 50 mg in addition 
to ongoing digitalis, diuretic, vasodilator and antiarrhythmic 
therapy as clinically indicated. Twenty-four hour electro•
cardiography was repeated 48 hours after the initiation of 
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oral milrinone therapy. Patients were evaluated monthly on 
an outpatient basis during long-term oral milrinone therapy, 
under a protocol approved by the Hospitals' Human Subjects 
Committees. At each visit, patients were evaluated by in•
terview and physical examination, and medication doses 
were changed as required. The dose of furosemide was 
altered to maintain an edema-free state, whereas the doses 
of the vasodilator and milrinone were adjusted to obtain 
maximal improvement in clinical symptoms. In the event 
of death outside the study hospital, information was obtained 
from the patient's family and physician. When possible, the 
cause of death was ascribed either to progressive heart fail•
ure or to sudden death (death occurring in the absence of 
premonitory symptoms during the previous hour, in a patient 
who was otherwise clinically stable). 
Statistical analysis. Clinical and hemodynamic vari•
ables at baseline and during milrinone therapy were eval•
uated for the 100 patients as a whole and for several subgroups 
based on survival outcome. Data were expressed as mean 
± SD, and initial univariate comparisons were made using 
either an unpaired t test or 2 x 2 frequency table (chi•
square) analysis, with statistical significance taken at prob•
ability (p) less than 0.05. Multivariate analysis was sub•
sequently performed using discriminant analysis (24,25). 
Cumulative survival curves were obtained for the group as 
a whole and for various clinical subgroups, using both the 
life table (26) and Kaplan-Meier (27) survivorship methods, 
in which patients withdrawn from milrinone therapy were 
treated as "dropouts" according to the first method and as 
"censored data" according to the second method. Life table 
survivor curves were tested for significant differences by 
standard methods, whereas the Kaplan-Meier curves were 
compared using both the Mantel-Cox log rank test (28) and 
the Gehan-Breslow statistic (29). 
Results 
Baseline findings. Patient characteristics are summa•
rized in Table 1. The mean duration of heart failure was 34 
months, and 95 patients had experienced significant wors•
ening of heart failure during the 6 months before entry. The 
cause of heart failure was ischemic heart disease in 58 pa•
tients, the majority of whom had obstructive coronary dis•
ease involving three vessels. Twenty-six (45%) of the pa•
tients with ischemic heart disease had previously undergone 
coronary artery bypass surgery. Congestive heart failure was 
due to dilated cardiomyopathy in 42 patients; dilated car•
diomyopathy followed adriamycin treatment in 2 patients, 
occurred in the setting of moderate alcohol intake in 2 pa•
tients, followed valve replacement in 5 patients and was 
idiopathic in the remaining 33 patients. 
Despite conventional therapy as described earlier, 39 pa•
tients were in functional class IV before milrinone therapy, 
and the remaining 61 were in functional class III. Hemo-
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Table 1. Patient Characteristics by Survival Outcome 
Clinical variable 
Age (yr) 
Male (%) 
NYHA class IV 
(%) 
CAD(%) 
with CABG 
(% of CAD) 
LVEF(%) 
RVEF(%) 
BUN (mg/dl) 
Creatinine (mg/dl) 
VT> 3 
Baseline (%) 
Milrinone (%) 
Concomitant drugs 
(mg/day)* 
Milrinone 
Discharge 
Last follow-up 
Furosemide 
Discharge 
I Month 
Last follow-up 
Antiarrhythmic 
drug 
Captopnl 
Discharge 
Last follow-up 
Hemodynamicst 
RAP (mm Hg) 
BaselIne 
Milrinone 
PCWP (mm Hg) 
Baseline 
MIlrinone 
AoSP (mm Hg) 
Baseline 
Milrinone 
CI (liters/min per 
m") 
Baselme 
Mllrinone 
SVR 
(dynesos-cm -5) 
Baseline 
Milnnone 
L VSWI (gomlm2) 
BaselIne 
Milrinone 
RVSWI (gomlm2) 
Baseline 
Total Group 
(n = 1(0) 
59 ± 12 
79 
39 
58 
45 
17 ± 8 
28 ± 17 
31 ± 18 
16 ± 0.6 
59 
68 
27 ± 8 
34 ± II 
108 ± 54 
105 ± 74 
151 ± 97 
56% 
32% (57 ± 39) 
36% (57 ± 56) 
13 ± 7 
8 ± 5 (-38%) 
28 ± 7 
18 ± 9 (-34%) 
108 ± 19 
104 ± 18 (-3%) 
2.0 ± 0.6 
2.9 ± 0.8(+51%) 
1,603 ± 583 
1.085 ± 429 
(-32%) 
22 ± 10 
32 ± 13 (+57%) 
\3 ± 5 
Survivors> 6 Months 
(n = 25) 
57 ± 15 
84 
28 
56 
50 
18 ± 8 
35 ± 19 -p < 002-
26 ± 13 -p < 0.01-
1.4 ± 0.5 -p < 0.01-
33 -p < 002-
52 
28 ± 9 
36 ± II 
88 ± 54 
83 ± 68 
126 ± 85 
44% 
40% (49 ± 43) 
40% (68 ± 84) 
II ± 7 -p < 001-
7 ± 5 (-35%) 
27 ± 6 
17 ± 10 (-38%) 
118 ± 32 -p < 0.05-
108 ± 22 (-8%) 
2.1 ± 0.6 -p < 0.01-
2.9 ± 0.7 (+43%) 
1,664 ± 480 
1.156 ± 518 
(-29%) 
27 ± 12 -p < 0.01-
36 ± 17 (+42%) 
14 ± 6 -p < 0.05-
Nonsurvivors 
(n = 48) 
61 ± II 
75 
46 
54 
50 
17 ± 7 
24 ± 13 
36 ± 20 
1.8 ± 0.7 
62 
73 
26 ± 6 
36 ± 12 
122 ± 54 
123 ± 80 
170 ± 109 
56% 
330/c (52 ± 21) 
38% (41 ± 23) 
16 ± 7 
9 ± 5 (-40%) 
29 ± 7 
19 ± 9 (-37%) 
106 ± 16 
104 ± 17 (-1%) 
1.8 ± 0.4 
2.7±07(+58%) 
1,703 ± 670 
1.I15±411 
(-30%) 
18 ± 6 
29 ± II (+ 69% ) 
12 ± 5 
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Sudden Death 
(n = 15) 
63 ± 8 
37 
53 
73 
45 
19 ± 8 
29 ± 10 
36 ± 20 
1.8 ± 0.7 
67 
80 
24 ± 6 
29 ± 10 
119 ± 38 
94 ± 52 
113 ± 72 -p < 0.01-
73% -p < 0.05-
40% (56 ± 26) 
33% (38 ± 23) 
15 ± 6 
8 ± 6 (-48%) 
27 ± 7 
17 ± 8 (-38%) 
106 ± 15 
107 ± 18 (+1%) 
1.7 ± 0.3 
2.7 ± 0.8 (+57%) 
1,611 ± 402 
1.145 ± 486 
(-30%) 
19 ± 6 
30 ± 7 (+62%) 
12 ± 5 
CHF Death 
(n = 21) 
61 ± 10 
76 
38 
52 
45 
18 ± 8 
24 ± 15 
40 ± 24 
1.8 ± 0.9 
52 
67 
26 ± 7 
41 ± 13 
III ± 61 
152 ± 95 
214 ± 109 
38% 
24% (50 ± 23) 
33% (42 ± 24) 
15 ± 7 
9 ± 4 (-39%) 
30 ± 7 
19 ± 8 (-38%) 
100 ± 15 
98 ± 15 (-1%) 
1.8 ± 0.4 
2.8 ± 0.7 (+56%) 
1,565 ± 576 
998 ± 351 
(-39%) 
17 ± 5 
29 ± 12 ( + 76%) 
13 ± 5 
*Drug doses are shown as mean ± SD (in mg/day), at the time of hospital discharge (Discharge) and at the time of last follow-up. Percent figures 
for antIarrhythmIC drug and captopril refer to percent of patIents receiving the given drug or drug class at the time indicated, with the captopril dose 
(mean ± SD in mg/day) given m parentheses. tValues are shown at baselIne and after intravenous milrinone, with the percent change after milrinone 
indicated in parentheses. AoSP = aortic systolic pressure; BUN = blood urea nitrogen; CABG = coronary artery bypass graft; CAD = coronary artery 
disease; CHF = congestive heart failure; CI = cardiac mdex; L VEF = left ventricular ejection fraction; L VSWI = left ventricular stroke work index; 
NYHA = New York Heart Association; PCWP = pUlmonary capillary wedge pressure; RAP = right arterial pressure; RVEF = nght ventncular 
ejection fraction; RVSWI = nght ventricular stroke work index; SVR = systemic vascular resistance; VT > 3 = percent of patIents with at least one 
episode of ventricular tachycardia exceeding three beats m length on 24 hour ambulatory electrocardIOgraphy. 
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dynamic studies showed severe depression of ventricular 
performance (Table I). The baseline plasma norepinephrine 
at rest in the 29 patients in whom it was measured was 
markedly elevated, averaging 709 ± 616 pg/ml (normal 
value = 213 ± 60); this group did not differ significantly 
from the remaining 71 patients according to any of the 
variables in Table I. High grade ventricular arrhythmia was 
common (Fig. I); 24 hour electrocardiograms obtained be•
fore administration of milrinone showed at least one episode 
of non sustained asymptomatic ventricular tachycardia (three 
or more consecutive ventricular premature complexes) in 
57 patients. Episodes of ventricular tachycardia were three 
to six cycles in length in 35 patients and greater than six 
consecutive beats in an additional 22 patients, despite on•
going antiarrhythmic drug treatment (with quinidine or pro•
cainamide) in 56% of patients at the time of study entry. 
Acute effects of milrinone. Significant hemodynamic 
improvement was evident after the acute intravenous admin•
istration of milrinone 5 ± 3 mg (80 ± 40 j.tg/kg) (Table 
I). Repeat 24 hour electrocardiographic monitoring after 48 
hours of oral rnilrinone therapy showed no significant change 
in ventricular ectopic rhythm, with episodes of nonsustained 
asymptomatic ventricular tachycardia of three to six beats 
in length in 44 patients, and episodes exceeding six beats 
in length in an additional 20 patients (Fig. 1). Comparing 
pre- and post-milrinone 24 hour electrocardiographic re•
cordings in 97 patients, the level of ventricular arrhythmia 
increased in 23, decreased in 23 and remained unchanged 
in 51 patients. 
Clinical response to long-term therapy. Oral milri•
none therapy at an average initial dose of 27 ± 8 mg/day 
was associated with a decrease in the symptoms of heart 
failure in 48 of the 94 patients whose data are shown in 
Figure 2 (the 6 additional patients in the total group of 100 
had been followed up for less than I month after entry by 
January 1, 1985). If the nine patients who died during the 
first month of therapy and the three patients who were with•
drawn during the first month of the study are excluded (see 
later), heart failure symptoms improved by at least one 
functional class in 48 (59%) of 82 patients, were unchanged 
Figure 1. Highest grade of ventricular ectopic activity (VEA) on 
24 hour ambulatory electrocardiogram at baseline and after 48 
hours of oral milrinone therapy. FREQ. = frequent; OCCA. = 
occasional; VPB's = ventricular premature beats; VT = ventric•
ular tachycardia. 
BASELINE MILRINONE 
NOVEA IT] 0 
OCCAS [JQJ m VPB'. 
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Figure 2. New York Heart Association (NYHA) symptomatic 
class at baseline and after I month of milrinone therapy, in the 
94 patients followed up for at least I month. 
in 30 (35%) and worsened by one functional class in only 
4 (5%). 
This improvement could not be explained by an increase 
in furosemide dose, which was unchanged from 107 ± 68 
mg/day before milrinone to 105 ± 74 mg/day at 1 month. 
Nor could it be explained by the concomitant use of con•
ventional vasodilators, which were reduced significantly in 
both number of patients treated and dose per patient. While 
51 patients had received captopril at a dose that averaged 
105 ± 75 mg/day before milrinone therapy, only 24 patients 
continued to receive captopril at the I month visit and their 
dose was reduced to 57 ± 39 mg/day (p < 0.01). Similarly, 
only 3 of 13 patients continued to receive prazosin, and 
only 2 of 16 patients continued to receive hydralazine. Dur•
ing the 9 ± 5 months of follow-up, the dose of milrinone 
Figure 3. Survival curve for the 100 patients receiving chronic 
oral milrinone therapy. The figures at the bottom refer to the 
number of patients at risk at the indicated times. 
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was increased to an average of 34 ± 11 mg/day, and the 
dose of furosemide to 151 ± 97 mg/day, but there was no 
significant increase in concomitant vasodilator use or dosage 
(Table 1), 
Side effects and patient withdrawal. During the course 
of the study, 14 patients were withdrawn from milrinone 
therapy, Withdrawal was prompted by lack of response in 
three patients, poor compliance with the study protocol in 
two patients and surgical intervention obviating further mil•
rinone therapy in five patients (one aortic valve replacement 
at 10 months, one mitral valve replacement at 4 months and 
three cardiac transplantations at 0.25, 3 and 14 months, 
respectively), An additional four patients were withdrawn 
because of side effects possibly related to milrinone therapy, 
including one patient each with headache, muscular weak•
ness, insomnia and increased ventricular arrhythmia. Milder 
side effects occurred in seven patients. but did not prevent 
continuation of milrinone therapy; four of these patients 
reported headache during the initial days of milrinone ther•
apy, which subsequently resolved. Muscular weakness 
worsened after several months of therapy in one other patient 
with preexisting muscular dystrophy, but failed to improve 
after 1 week of milrinone withdrawaL so that milrinone was 
reinstituted to control ongoing symptoms of heart failure. 
An increase in anginal symptoms was reported by three 
patients during the increased activity permitted by the con•
trol of heart failure symptoms, but was managed by addi•
tional medical therapy in two patients and by coronary artery 
bypass grafting in the third. One patient sustained an acute 
myocardial infarction during milrinone therapy; this patient 
had undergone coronary artery bypass graft surgery 5 years 
before study entry, sustained a lateral wall myocardial in•
farction due to graft thrombosis after 9 months of milrinone 
Figure 4. Survival curves for patients with coronary artery dIsease 
(CAD) and dilated cardiomyopathy (CM). 
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Figure S. Survival curves for patients with NYHA class III and 
IV symptoms at study entry. 
therapy and died of progressive heart failure 2 months later. 
Mortality. Despite the aforementioned hemodynamic 
and clinical improvements and a relatively low incidence 
of side effects requiring discontinuation or reduction of the 
dose of milrinone. a substantial early mortality rate was 
noted (Fig. 3). Life table analysis disclosed a 39% mortality 
rate after 6 months, and a 63% mortality rate after 12 months 
of milrinone therapy. The 6 and 12 month mortality rates 
were not significantly different (40 and 75%) for the subgroup 
of patients whose baseline plasma norepinephrine levels at 
rest had been measured. 
Predictors of early mortality. Comparison of the 25 
patients who survived for more than 6 months with the 48 
patients who died during milrinone therapy reveals several 
univariate correlates of early mortality (Table I). Patients 
surviving for more than 6 months had significantly higher 
baseline right ventricular ejection fraction, systolic aortic 
pressure, cardiac index and left ventricular stroke work in•
dex than did nonsurvivors. Survivors also had significantly 
lower baseline values for blood urea nitrogen and creatinine, 
a lower incidence of ventricular tachycardia on the baseline 
24 hour ambulatory electrocardiogram and a lower baseline 
right atrial pressure than did nonsurvivors. Other factors, 
including the magnitude of the acute hemodynamic response 
to intravenous milrinone, did not correlate with survival. 
Multivariate analysis selected baseline cardiac index and 
systolic arterial pressure as the key variables defining sur•
vival outcome. 
Additional factors corresponding to early mortality dur•
ing milrinone therapy were evident using life table analysis. 
Although there was no difference in survival between pa•
tients with coronary artery disease (with or without prior 
bypass surgery) and patients with dilated cardiomyopathy 
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(Fig. 4), a significantly lower mortality was observed in 
patients who at baseline were in functional class III than 
was observed in those in class IV (39 versus 50% at 6 
months, and 54 versus 76% at 12 months, respectively) 
(Fig. 5). Patients whose heart failure symptoms had shown 
improvement by one or more functional classes after 1 month 
of milrinone therapy also had a significantly lower subse•
quent mortality than did patients without such improvement 
(23 versus 45% at 6 months) (Fig. 6). Finally, patients 
without episodes of ventricular tachycardia on the baseline 
24 hour ambulatory electrocardiogram had a significantly 
lower mortality than did patients with such episodes (37 
versus 52% at 6 months, and 52 versus 89% at 12 months, 
respectively) (Fig. 7). Although survivors also tended to be 
less likely to exhibit episodes of ventricular tachycardia 
while receiving oral milrinone, neither the level of arrhyth•
mia during milrinone therapy nor the relation between base•
line and post-milrinone ectopic activity was a statistically 
significant predictor of early mortality. 
Mode of death. The mode of death could be classified 
in 36 of the 48 patients who died during chronic milrinone 
therapy; 15 patients sustained sudden death after 5 ± 4 
months, whereas 21 patients died of progressive heart failure 
after 4 ± 3 months. Not unexpectedly, patients dying of 
progressive heart failure received greater increases of doses 
of both milrinone and furosemide during the course of the 
study, compared with the subgroup of patients who died 
suddenly and the subgroup of patients surviving longer than 
6 months. While patients dying suddenly were more likely 
to be receiving antiarrhythmic drugs, neither the prevalence 
of ventricular tachycardia on the baseline or post-milrinone 
Figure 6. Survival curves for patients who did and did not improve 
their symptomatic status by one or more NYHA classes after 1 
month of oral milrinone therapy. 
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Figure 7. Survival curves for patients with and without episodes 
of nonsustained ventricular tachycardia (VT) on the baseline 24 
hour ambulatory electrocardiogram. 
24 hour ambulatory electrocardiogram nor the hemody•
namics at baseline or after intravenous milrinone were sig•
nificant predictors of sudden death as opposed to death from 
progressive heart failure. 
Discussion 
Hemodynamic and clinical effects of milrinone. 
Milrinone is a methyl, carbonitrile derivative of the earlier 
bipyridine agent amrinone, which has been approved for 
intravenous use in the short-term treatment of severe conges•
tive heart failure. Both animal and clinical studies have 
shown milrinone to have 10 to 30 times the potency of the 
parent compound (30). Its mechanism of action relates in 
part to selective inhibition of phosphodiesterase in cardiac 
and vascular smooth muscle. Other direct effects on calcium 
handling have been suggested, but milrinone, like amrinone, 
does not appear to inhibit sodium-potassium adenosine tri•
phosphatase as do cardiac glycosides, nor does it stimulate 
beta-adrenergic or histaminergic receptors (30). Although 
milrinone does act on vascular smooth muscle to produce 
significant direct peripheral vasodilation (31), several stud•
ies have demonstrated a clear positive inotropic effect at 
therapeutic plasma concentrations. These studies include 
demonstration of an increase in peak positive left ventricular 
first derivative of pressure (dP/dt)-which is not observed 
with pure vasodilators such as nitroprusside-during both 
intravenous (16,32) and low dose intracoronary (33) mil•
rinone administration to patients with heart failure, as well 
as an increase in the slope of the end-systolic pressure•
dimension relation in normal subjects (34). In addition to 
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these vasodilator and positive inotropic effects. milrinone 
also appears to improve diastolic left ventricular function 
in patients with heart failure (35). The aggregate effect of 
these several actions on the patient with severe heart failure 
is a marked acute hemodynamic improvement after acute 
intravenous milrinone administration. 
Recent studies have suggested that oral administration of 
milrinone, 30 to 40 mg/day in divided doses, produces com•
parable acute hemodynamic effects and few drug-related 
side effects (16.19,36). These hemodynamic benefits appear 
to persist during 1 month of chronic oral therapy, are as•
sociated with improvements in exercise tolerance (20) and 
led to a reduction in clinical symptoms in approximately 
one-half of patients who had failed to respond adequately 
to conventional therapy (19). Moreover, this experience 
with long-term oral milrinone therapy contrasts with the 
earlier bipyridine amrinone, which caused adverse reactions 
in 83% of patients (requiring drug withdrawal in 34% of 
patients), and in a multicenter trial (37) failed to cause 
significant symptomatic improvement at maximally toler•
ated doses. 
Mortality: comparison with prior studies. Despite the 
preceding observations, long-term milrinone therapy was 
associated with a substantial early mortality in our patients; 
39% were dead within 6 months and 63% were dead within 
1 year of the beginning of therapy. This appears somewhat 
better than the experience of Simonton et al. (19). who 
reported a 6 month mortality of 66% in 37 patients with a 
more advanced average functional class and a slightly lower 
average stroke work index. treated with a higher milrinone 
dose averaging 48 mg/day. Several patient characteristics 
at entry correlated with early mortality in our study, in•
cluding functional class, renal function. ventricular ectopic 
activity, hemodynamic function (right atrial pressure. sys•
tolic arterial pressure, cardiac index. left and right ventric•
ular stroke work index, right ventricular ejection fraction) 
and the clinical response to 1 month of oral milrinone ther•
apy. Although many of these variables have been previously 
identified as predictors of early mortality in studies of pa•
tients with heart failure treated with conventional agents 
(digitalis, diuretic agents or vasodilators, or both) (1-12), 
accurate comparison of survival outcome in the current study 
with that expected for patients with comparably severe heart 
failure is difficult. 
One example of the complexity of comparing different 
patient populations with heart failure is the use of entry 
functional class, which has constituted an important pre•
dictor of survival outcome in virtually all trials. However. 
patients entering the current study with functional class IV 
heart failure despite vasodilator therapy might have more 
advanced disease than patients entering prior studies with a 
similar degree of heart failure in the absence of a potent 
vasodilator. Selection of an appropriate comparison group 
would require matching of other hemodynamic and clinical 
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variables as well. Vasodilator-treated patients with a com•
parable mean baseline plasma norepinephrine level of 700 
pg/ml have been reported by Cohn et al. (38) to have a 1 
year mortality rate of approximately 50%. which is similar 
to the mortality in the three prior vasodilator trials in which 
the mean baseline left ventricular stroke work index was 
below 25 g.mlm2 (5.8,38). The presence of ventricular ec•
topic activity may also influence survival (5,11,12). In a 
study of 35 vasodilator-treated heart failure patients with 
hemodynamic dysfunction and ventricular ectopic activity 
comparable with that observed in our patient population, 
Maskin et al. (39) reported a 1 year mortality rate in excess 
of 60%. Thus, the 63% 1 year mortality rate in our study 
is clearly at or above that reported in previous vasodilator 
trials. This may be explicable in part by our selection of 
patients who had severe heart failure despite therapy with 
conventional vasodilators and who may therefore have had 
more advanced disease; however. given the difficulties in 
selecting an appropriate comparison group, it would be im•
possible to exclude a concomitant adverse effect of milri•
none on patient survival except by performance of a pro•
spective randomized trial. 
Potential mechanisms of mortality. An alternative ap•
proach to evaluating the effect of milrinone on patient sur•
vival would be to examine the individual mechanisms by 
which adverse effects might be mediated: worsening of isch•
emia, a proarrhythmic effect or hastening the development 
of myocardial cell death or dysfunction. 
Myocardial ischemia. Because of the frequent presence 
of epicardial coronary stenoses, high left ventricular wall 
stress at rest and decreased effective coronary perfusion 
pressure, patients with advanced congestive heart failure 
may be particularly sensitive to agents that worsen the im•
balance between myocardial oxygen supply and demand 
(40). However. previous clinical studies (41) suggest that 
both amrinone and milrinone increase hemodynamic per•
formance without significantly increasing myocardial oxy•
gen consumption, because of offsetting actions on the in•
dividual determinants of myocardial oxygen consumption 
(MV02 ). Although this may be an advantage of the bipyr•
idines as compared with sympathomimetic positive inotropic 
agents such as dobutamine (which increase MV02 by ap•
proximately 30% at doses that provide a comparable im•
provement in hemodynamic status [42]), it should be con•
trasted with pure vasodilators that may decrease MV02 by 
10 to 20%. There were no significant differences in the 
survival characteristics of milrinone-treated patients with 
and without underlying coronary artery disease, and wors•
ening of ischemic symptoms was uncommon in our study. 
In addition, the occurrence of only one documented myo•
cardial infarction during follow-up (that due to saphenous 
vein graft thrombosis) suggests that precipitation of overt 
ischemia by milrinone therapy would be an unlikely expla•
nation for the high mortality that was observed. This com-
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parative lack of adverse ischemic events in the current study 
contrasts with the observations of Packer et al. (23) in 29 
patients treated with oral amrinone, but nearly half of our 
patients with coronary artery disease had undergone prior 
bypass surgery, and patients with limiting angina had been 
excluded from entry into the study. 
Ventricular ectopic activity. A second mechanism by 
which inotropic agents have been postulated to worsen sur•
vi val is by enhancing ventricular ectopic activity. The pres•
ent and previous studies (5,11,12,39) demonstrate a high 
prevalence of nonsustained ventricular tachycardia in pa•
tients with advanced congestive heart failure, with or with•
out concomitant antiarrhythmic therapy. Our data support 
a relation between baseline episodes of nonsustained ven•
tricular tachycardia and subsequent cardiac mortality, but 
fail to demonstrate any significant correlation between the 
presence of this arrhythmia and the mode of death (sudden 
death versus death due to progressive heart failure). A more 
important concern, however, would be that milrinone may 
have increased ventricular ectopic activity or mortality, or 
both. In fact, therapeutic concentrations of milrinone may 
improve conduction and reduce postrepolarization refrac•
toriness in "ischemic gap" preparations (43), which could 
exert either a proarrhythmic or an antiarrhythmic effect in 
patients with areas of decremental conduction. On the other 
hand, our 24 hour ambulatory electrocardiographic moni•
toring data show no overall change in ventricular ectopic 
activity after milrinone administration, and no difference in 
subsequent mortality for the patients who showed a slight 
increase or decrease in ectopic activity on milrinone therapy. 
This lack of an overt proarrhythmic effect was recently 
substantiated by Goldstein et al. (44), who showed that 
intravenous milrinone did not change the incidence of ven•
tricular arrhythmia on electrocardiographic monitoring, and 
significantly reduced the inducibility of ventricular tachy•
cardia during programmed right ventricular stimulation. On 
the basis of these observations, there is not evidence that 
the high 1 year mortality observed during milrinone therapy 
can be explained by a pro arrhythmic effect. 
Myocardial degeneration. The final mechanism that has 
been suggested as a possible deleterious effect of inotropic 
therapy in heart failure is an acceleration of myocardial cell 
death due to "flogging" the failing heart (21-23). If this 
mechanism were operative, one would expect more rapid 
worsening of ventricular function in patients receiving long•
term oral inotropic therapy than could be explained simply 
by continued progression of the underlying heart disease. 
In this regard, Sinoway et al. (17) reported a reduction in 
drug-free stroke volume index in a group of seven patients 
who had received 2 to 9 weeks of oral milrinone therapy. 
It should be noted that 21 of our patients died of progressive 
heart failure after a mean of 4 months of treatment and that 
we observed a tendency for milrinone and furosemide doses 
to be increased as heart failure worsened with the passage 
lAce Vol 7. No 3 
March 1986661-70 
of time. On the other hand, Simonton et al. (19) reported 
no change in the drug-free cardiac index, pulmonary cap•
illary wedge pressure or stroke work index in 25 patients 
treated with milrinone for an average of 37 days, supporting 
our recent experience (45) in 13 patients who were restudied 
after 8 ± 4 months of continuous oral milrinone therapy 
and showed no worsening in average drug-free myocardial 
function or milrinone responsiveness after long-term treat•
ment. Although worsening of myocardial function thus does 
not seem to be an inevitable consequence of milrinone ther•
apy, a placebo-controlled study will be required to accu•
rately evaluate the possibility that milrinone therapy may 
affect-favorably or adversely-the rate of deterioration of 
myocardial function in excess of that expected simply as 
the result of the progression of the underlying cardiac disease 
in patients who receive conventional therapy alone. 
Limitations of study. The main limitations of the cur•
rent study are its open label design, use of a subjective end 
point (functional class) to determine clinical responsiveness 
(although the principal end point was mortality) and lack 
of a concurrent control popUlation treated with conventional 
therapy. In part, these limitations are inherent in the initial 
clinical investigation of a new inotropic agent in a patient 
popUlation with disabling symptoms despite conventional 
therapy. Until proposed randomized trials with milrinone 
are completed, however, careful analysis of detailed non•
randomized "data bank" studies provides the only means 
of assessing long-term drug safety and efficacy (I). 
A second limitation concerns the statistical treatment of 
patients withdrawn from the study. According to standard 
life table methods, these patients are treated as "lost to 
follow up" or "censored points" at the time of withdrawal. 
If preterminal patient withdrawal is used excessively, how•
ever, it may reduce apparent mortality and contribute to 
misleading results. In part because of the low incidence of 
side effects during long-term oral milrinone therapy, only 
14 patients were withdrawn, of whom only 5 might be 
considered suspect (2 patients with poor compliance with 
the protocol and 3 patients with lack of clinical response). 
Reanalysis of the data with continued inclusion of these five 
patients beyond the point of withdrawal does not signifi•
cantly alter the findings. 
Implications. Our experience in 100 patients with se•
vere congestive heart failure suggests that long-term oral 
milrinone therapy is well tolerated, and that significant clin•
ical improvement occurs initially in approximately one-half 
of patients whose symptoms had failed to respond ade•
quately to conventional therapy. Early mortality, however, 
remains at or above that reported in previous vasodilator 
trials. Although this may be due in part to more advanced 
hemodynamic derangement in our patients, it is impossible 
to exclude a contribution of milrinone therapy to poor overall 
survival. On the other hand, analysis of three potential 
mechanisms (increased ischemia, enhanced ventricular ec-
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topic activity, accelerated myocardial degeneration) do not 
suggest any single mechanism by which milrinone might 
worsen survival. Pending more definitive, appropriately 
blinded, placebo-controlled trials. it is important to realize 
that despite the initial salutary hemodynamic and clinical 
effects, therapy with milrinone does not appear to improve 
the prognosis of patients with advanced heart failure, and 
should not delay more definitive interventions such as car•
diac transplantation (46) in patients for whom this alternative 
is available, 
References 
Braunwald E, ColucCI WS EvaluatIng the efficacy of new InotroPIC 
agents 1 Am Coli Cardiol 1984,3.1570-4 
2. McKee PA, CastellI WP, McNamara PM, Kannel WB The natural 
history of congestIve heart failure: the FramIngham ~tudy N Engl 1 
Med 1971;285:441-6. 
3. CaliffRM, Bounow, P, Harrell FE, et al. The prognosIs In the presence 
of coronary artery disease In. BraunwaId E, Mock MB, Watson 1, 
eds. CongestIve Heart FaIlure. Current Research and ClInIcal ApplI•
cations. New York. Grune & Stratton, 1982.31-40. 
4. MaSSIe B, Port~ T, Chatterjee K, et al. Long-term vasodIlator therapy 
for heart faIlure. clInical response and Its relationshIp to hemodynamIC 
measurements CIrculatIon 1981 ;63:269-78 
5. WIlson lR, Schwartz lS, St 10hn Sutton M, et al. PrognosIs 10 severe 
heart faIlure' relationshIp to hemodynamic measurements and ven•
tncular ectopic actIVIty. 1 Am Coli Cardlol 1983,2'403-10 
6. Franclosa lA, Wilen M, Zelsche S, Cohn IN. SurVIval In men WIth 
~evere chrOnIC left ventncular faIlure due to eIther coronary heart 
dl~ease or IdIOpathic dilated cardIOmyopathy Am 1 CardlOl 
1983;51'831-6. 
7. Creager MA, Faxon DP, Helpenn lL, et al. DetermInant~ of clInIcal 
response and surVIval in patIents with congestIve heart faIlure treated 
WIth captopnl. Am Heart 1 1982;104:1147-54 
8. Walsh WF, Greenberg BH. Re~ulb of long-term va~odiiator therapy 
In patIents WIth refractory congestIve heart faIlure CIrculatIOn 
1981 ;64:499-505. 
9. Fuster V, Gersh Bl, GUIlIanI ER, Tajlka Al, Brandenburg RO, Frye 
RL. The natural hIstory of IdIOpathIC dIlated cardIOmyopathy Am 1 
Cardlol 1981 ;47:525-31 
10. Unverferth DV, Magonen RD, Moeschberger ML, Baker PB, Fetters 
lK, LeIer CV. Factors mfluencIng the one-year mortalIty of dIlated 
cardiomyopathy Am 1 CardlOl 1984;54:147-59 
II Holmes 1, Kubo SH, Cody Rl, Kligfield P ArrhythmIas 10 IschemIC 
and nOnIschemlc dIlated cardIOmyopathy: predIctIon of mortahty by 
ambulatory electrocardIOgraphy. Am 1 CardIOI1985,55.146-151 
12. MeInertz T, Hoffman T, Ka~per W, et al. SIgnIficance of ventncular 
arrhythmIas In IdIOpathIC dilated cardIOmyopathy. Am 1 CardlOl 
1984;53'902-7 
13 Packer M. Vasodilator and InOtroPIC therapy for severe chronIC heart 
faIlure: passIOn and skeptICIsm 1 Am Coli CardlOl 1983;2.841-52 
14. Captopril Multicenter Research Group. A placebo-controlled trial of 
captopnl in refractory chronIC congestive heart faIlure 1 Am Coli 
CardlOl 1983;2:755-63. 
15 Furberg CO, Yusuf S. Effect of vasodIlators on surVIval In chronIC 
heart faIlure (edltonal) Am 1 Cardlol 1985,55 1110-4 
16. Balm DS, McDowell A V, ChernIle~ 1, et al. EvaluatIOn of a new 
blpyndIne InOtropIC agent-milnnone-In patients WIth ~evere 
congestive heart failure N Engl 1 Med 1983:309:754-6. 
17. SInoway LS, MaskIn CS, ChadWIck B, Forman R, Sonnenbhck EH, 
BAlM ET AL 
SURVIVAL WITH ORAL MILRINONE 
669 
Lelemtel TH. Long-term therapy WIth a new cardiotOnIC agent, WIN 
47203' drug-dependent improvement In cardiac performance and pro•
gre~slOn of underlymg disease. 1 Am Coli Cardiol 1983;2:327-31. 
18. MaskIn CS, SInoway L, ChadWICk B, Sonnenbhck EH, Lelemtel TH. 
SustaIned hemodynamIC and clinical effects of a new cardiotOnIC agent, 
WIN 47203, In patIenb WIth severe congestIve heart failure. Circu•
latIOn 1983;67: 1065-70. 
19 SImonton C, Chatterjee K, Cody R, et al Mllnnone In congestIve 
heart faIlure: acute and chronIC hemodynamic and clInIcal evaluatIon. 
1 Am Coli CardlOl 1985;6-453-9 
20 WhIte HD, Rlbero lP, Hartley LH, ColUCCI WS ImmedIate effects 
of milnnone on metabolIc and sympathetIc responses to exercIse in 
severe conge~tive heart failure. Am 1 Cardlol 1985;56:93-8 
21 Katz AM A new inotropIC drug: its promIse and a cautIon. N Engl 
J Med 1978;299'1409-10 
11 LeJemtel TH, Sonnenblick EH. Should the faIlIng heart be ~tImulated? 
N Engl 1 Med 1984,310.1384-5 
23. Packer M, MedIna N, Yu~hak M Hemodynamic and clinical limi•
tatHln', of long-term InotropIC therapy with amnnone In patIents with 
,evere chronIC heart faIlure. CIrculatIOn 1984;70.1038-47. 
24 DIXon Wl, Brown MB BMDP-79 BIomedical Computer Programs, 
P senes Berkeley: UniverSIty of CalIfornIa Pre". 1979'517 10-.13, 
711-33 
25. lennnch RI Stepwise Dlscnminant AnalYSIS. In: EI~leIn K, Ralston 
A, Wilf HS, eds. StatIstIcal Methods for DIgital Computers New 
York' 10hn WIley & Sons, 1977:76-95 
26 Beahrs OH, Myers MH, eds. Manual for StagIng of Cancer 2nd ed. 
PhIladelphIa: LIppIncott 1983: 15-26 
27 Kaplan EL, MeIer P Nonparametnc estImatIon from Incomplete ob•
servatlOn;.l Am Stat A..sn 1958;53.457-81. 
28. Mantel N. EvaluatIon of surVIval data and two new rank order statistics 
arISIng In Its consIderatIOn. Cancer Chemother Rep 1966;50: 163-70 
29. Breslow N A generalized Kruskal-Wallis test for companng k samples 
subject to unequal patterns of censorshIp. BlOmetnka 1970;57:579-94 
30 Alousl AA, Canter 1M, Montenaro Ml, Fort Dl, Ferrari RA. Car•
diotOnIC actIVIty of milrinone, a new and potent cardIac bipyndIne, 
on the normal and falling heart of expenmental anImals. 1 CardlOvasc 
Pharmacol 1983,5:792-803 
31 Kubo SH, Muller FB, Rutman H, Leonard D. Va~odllator propertIes 
of miinnone an Intra-arterial study (abstr). CIrculatIOn 1984;70(suppl 
11).11-11. 
32 Ja,kl BE. FIfer MA, Wright RF, Braunwald E. Colucci WS. PosItIve 
InotropIC and vasodIlator action, of milnnone in palIenh WIth severe 
congestIve hedrt faIlure J Clin Inve,t 1985,75:643-9. 
.13 Ludmer PL. Wnght RF, Arnold JMO, Ganz P, Braunwald E, ColUCCI 
W SeparalIon of the direct myocardIal and vasodIlator actions of 
miinnone. ,tudles using an Intracoronary InfUSIOn technIque. Circu•
latIOn (In pre,,) 
34 Borow KM, Come PC, Neumann A, Balm DS, Braunwald E, Gro,,•
man W. PhYSIOlogic assessment of the InOtroPIC, vasodilator and after•
load reducing effects of milrinone In subjects without cardIac disease 
Am J Cardiol 1985;55.1204-9 
35 Monrad ES, McKay RG, BaIrn DS, et al. Improvement In mdexes of 
dIastolic performance In patIent~ WIth conge,tIve heart faIlure treated 
wIth milrinone. CIrculatIon 1984,70.1030-7. 
36. Kubo SH, Cody Rl, Chatterjee K, Simonton C, Rutman H, Leonard 
D Acute dose range ,tudy of mIlrInone In congestive heart failure. 
Am 1 CardIOI 1985:55:726-30. 
37 Massie B, Bourassa M, DIBlanco R, et al Long-term oral adminis•
tralIon of amrinone for congestive heart failure. lack of efficacy in a 
multIcenter controlled trial Circulation 1985;71 :963-71. 
38. Cohn IN, Levine TB, Olivari MT, et al Plasma norepinephrine as a 
gUIde to progno'ls In patients WIth chromc congestive heart failure. 
N Engl J Med 1984;311:819-23. 
670 BAlM ET AL 
SURVIVAL WITH ORAL MILRINONE 
39. Ma,km CS, Siskind SJ. LeJemtel TH. High prevalence of nonsus•
tained ventricular tachycardia in severe congestive heart failure. Am 
Heart J 1984,107:896-901. 
40. Unverferth DV, Margorien RD, LewIs RP, LeIer CV. The role of 
subendocardial Ischemia in perpetuating myocardial faIlure in patIents 
WIth non ischemic congestive cardiomyopathy. Am Heart J 
1983;105.176-9. 
41. Monrad ES, Bairn DS, SmIth HS, Lanoue A, Braunwald E, Grossman 
W. Effects of mllrinone on coronary hemodynamIcs and myocardial 
energetics in patients with congestIve heart failure. Circulation 
1985;71:972-9. 
42. Monrad ES, Bairn DS, Smith HS, Lanoue AS. Milrinone, dobutamme, 
and nitroprusside: comparative effects on hemodynamics and myo-
lACC Vol 7. No 3 
March 1986 661-70 
cardial energetics m patients with severe congestIve heart fmlure. 
CIrculation (m press) 
43. Davldenko JM, Antezelevltch C. The effects of mllrinone on con•
duction, reflection, and automatIcity m canme PurkmJe fibers. Cir•
culation 1984;69: 1026-35. 
44. Goldstein RA, GeracI SA, Gray EL, Rinkenberger RL, Dougherty 
AH, Naccarelli G V. Electrophysiologic effects of milrinone in conges•
tive heart faIlure. Am J Cardiol (m pres,). 
45 Monrad ES, Bairn DS, Smith HS, et al. Assessment of long-term 
inotropIc therapy with milrinone and the effects of milrinone with•
drawal. Circulation (m press). 
46. Oyer PE, JamIeson SW, Stinson EB. CardIac transplantatIon for end•
stage congestive heart faIlure. In Ref. 3: 317-27. 
